Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
BEIJING–(BUSINESS WIRE)– Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an...